Intravenous tenoxicam reduces uterine cramps after Cesarean delivery.
OBJECTIVE
Postpartum uterine contraction pain is a common phenomenon after Cesarean delivery. We investigated the effectiveness of tenoxicam in reducing uterine contraction pain.


METHODS
We enrolled 120 consecutive non-breastfeeding women who were scheduled for elective Cesarean delivery. After the administration of spinal anesthesia with bupivacaine and intrathecal morphine 0.15 mg injection, the patients were randomly divided into two groups. Group I received placebo (normal saline) iv injection, and Group II received tenoxicam 40 mg iv injection after clamping the umbilical cord. Verbal analogue scale of wound pain and uterine contraction pain were recorded at two, four, eight,16, and 24 hr after Cesarean delivery.


RESULTS
There was no significant difference in wound pain scores between the two groups (all scores < or =3). However, the tenoxicam group had significant lower uterine contraction pain scores and required less supplemental meperidine medication than did the placebo group (8.5% vs 41.4%, P <0.05). The incidences of nausea or vomiting, pruritus, and bleeding were not significantly different between groups.


CONCLUSIONS
Intravenous tenoxicam 40 mg significantly reduced the intensity of uterine cramps in patients undergoing Cesarean delivery without increasing side effects.
Huang
Yu-Chen
YC
Department of Anesthesiology, National Taiwan University Hospital, College of Medicine and Hospital, Taipei, Taiwan.
Tsai
Shen-Kou
SK
Huang
Chi-Hsiang
CH
Wang
Mao-Hsien
MH
Lin
Pei-Lin
PL
Chen
Li-Kuei
LK
Lin
Chen-Jung
CJ
Sun
Wei-Zen
WZ
D000328:Adult; D000758:Anesthesia; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002585:Cesarean Section; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy*; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000453:epidemiology; D011247:Pregnancy; D011446:Prospective Studies; D014590:Uterine Contraction / Q000502:physiology; D014591:Uterine Diseases / Q000188:drug therapy* / Q000209:etiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam